Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
Timo Purmonen,1 Kari Puolakka,2 Dinesh Mishra,3 Praveen Gunda,3 Janne Martikainen4 1Novartis Finland Oy, Espoo, Finland; 2South Karelia Central Hospital, Lappeenranta, Finland; 3Novartis Product Lifecycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India; 4School of Pharmacy, Unive...
Published in: | ClinicoEconomics and Outcomes Research |
---|---|
Main Authors: | , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Press
2019
|
Subjects: | |
Online Access: | https://www.dovepress.com/cost-effectiveness-of-secukinumab-compared-to-other-biologics-in-the-t-peer-reviewed-fulltext-article-CEOR |
id |
ftdovepress:oai:dovepress.com/44123 |
---|---|
record_format |
openpolar |
spelling |
ftdovepress:oai:dovepress.com/44123 2023-05-15T17:00:00+02:00 Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland Purmonen,Timo Puolakka,Kari Mishra,Dinesh Gunda,Praveen Martikainen,Janne 2019-02-15 text/html https://www.dovepress.com/cost-effectiveness-of-secukinumab-compared-to-other-biologics-in-the-t-peer-reviewed-fulltext-article-CEOR en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/CEOR.S192235 https://www.dovepress.com/cost-effectiveness-of-secukinumab-compared-to-other-biologics-in-the-t-peer-reviewed-fulltext-article-CEOR info:eu-repo/semantics/openAccess ClinicoEconomics and Outcomes Research Original Research info:eu-repo/semantics/article 2019 ftdovepress https://doi.org/10.2147/CEOR.S192235 2022-12-27T22:32:59Z Timo Purmonen,1 Kari Puolakka,2 Dinesh Mishra,3 Praveen Gunda,3 Janne Martikainen4 1Novartis Finland Oy, Espoo, Finland; 2South Karelia Central Hospital, Lappeenranta, Finland; 3Novartis Product Lifecycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India; 4School of Pharmacy, University of Eastern Finland, Kuopio, Finland Aim: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. Methods: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pegol, etanercept, etanercept biosimilar, golimumab, and infliximab in a biologic-naïve population over a lifetime horizon. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess the treatment response. Efficacy inputs were obtained from the network meta-analysis, and other model inputs were obtained from the published literature and Finnish sources. Main study outcomes included quality-adjusted life years (QALYs) gained and incremental cost-effectiveness ratio in terms of cost per QALY gained. Robustness of results was confirmed by sensitivity analyses and alternative scenario analyses. Results: Secukinumab achieved highest QALYs (13.1) at lowest expected lifetime cost (€279,872) vs other comparators in biologic-naïve AS patients in the base case analysis, thus it dominated other biologics. Golimumab had a second highest QALYs (12.9) at the total cost of €309,551. Results were sensitive to variation in BASDAI 50 response for secukinumab, baseline Bath Ankylosing Spondylitis Functional Index (BASFI) score across all drugs, change in BASDAI and BASFI scores, and discount rates as observed in the one-way sensitivity analyses. Secukinumab was either dominant or cost-effective treatment in different alternative scenarios. Conclusion: Secukinumab presented itself to be the dominant (ie, less costly and more effective) treatment vs other comparators for the ... Article in Journal/Newspaper karelia* Dove Medical Press Kari ENVELOPE(28.979,28.979,66.201,66.201) ClinicoEconomics and Outcomes Research Volume 11 159 168 |
institution |
Open Polar |
collection |
Dove Medical Press |
op_collection_id |
ftdovepress |
language |
English |
topic |
ClinicoEconomics and Outcomes Research |
spellingShingle |
ClinicoEconomics and Outcomes Research Purmonen,Timo Puolakka,Kari Mishra,Dinesh Gunda,Praveen Martikainen,Janne Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland |
topic_facet |
ClinicoEconomics and Outcomes Research |
description |
Timo Purmonen,1 Kari Puolakka,2 Dinesh Mishra,3 Praveen Gunda,3 Janne Martikainen4 1Novartis Finland Oy, Espoo, Finland; 2South Karelia Central Hospital, Lappeenranta, Finland; 3Novartis Product Lifecycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India; 4School of Pharmacy, University of Eastern Finland, Kuopio, Finland Aim: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. Methods: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pegol, etanercept, etanercept biosimilar, golimumab, and infliximab in a biologic-naïve population over a lifetime horizon. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess the treatment response. Efficacy inputs were obtained from the network meta-analysis, and other model inputs were obtained from the published literature and Finnish sources. Main study outcomes included quality-adjusted life years (QALYs) gained and incremental cost-effectiveness ratio in terms of cost per QALY gained. Robustness of results was confirmed by sensitivity analyses and alternative scenario analyses. Results: Secukinumab achieved highest QALYs (13.1) at lowest expected lifetime cost (€279,872) vs other comparators in biologic-naïve AS patients in the base case analysis, thus it dominated other biologics. Golimumab had a second highest QALYs (12.9) at the total cost of €309,551. Results were sensitive to variation in BASDAI 50 response for secukinumab, baseline Bath Ankylosing Spondylitis Functional Index (BASFI) score across all drugs, change in BASDAI and BASFI scores, and discount rates as observed in the one-way sensitivity analyses. Secukinumab was either dominant or cost-effective treatment in different alternative scenarios. Conclusion: Secukinumab presented itself to be the dominant (ie, less costly and more effective) treatment vs other comparators for the ... |
format |
Article in Journal/Newspaper |
author |
Purmonen,Timo Puolakka,Kari Mishra,Dinesh Gunda,Praveen Martikainen,Janne |
author_facet |
Purmonen,Timo Puolakka,Kari Mishra,Dinesh Gunda,Praveen Martikainen,Janne |
author_sort |
Purmonen,Timo |
title |
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland |
title_short |
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland |
title_full |
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland |
title_fullStr |
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland |
title_full_unstemmed |
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland |
title_sort |
cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in finland |
publisher |
Dove Press |
publishDate |
2019 |
url |
https://www.dovepress.com/cost-effectiveness-of-secukinumab-compared-to-other-biologics-in-the-t-peer-reviewed-fulltext-article-CEOR |
long_lat |
ENVELOPE(28.979,28.979,66.201,66.201) |
geographic |
Kari |
geographic_facet |
Kari |
genre |
karelia* |
genre_facet |
karelia* |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.2147/CEOR.S192235 https://www.dovepress.com/cost-effectiveness-of-secukinumab-compared-to-other-biologics-in-the-t-peer-reviewed-fulltext-article-CEOR |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.2147/CEOR.S192235 |
container_title |
ClinicoEconomics and Outcomes Research |
container_volume |
Volume 11 |
container_start_page |
159 |
op_container_end_page |
168 |
_version_ |
1766052632197070848 |